top of page

Our progress is supported by renowned institutions: 

NASA
Bristol University
Imperial College London
ISS
BIDMC
Harvard
NIAID
CDMRP
queen mary university

Developing first-in-class therapeutics 

​

Disease/Injury manipulates the ICE to enable its progression; reverting ICE changes makes it possible to develop treatment for every disease. 

​​

MicroQuin focuses in-house efforts on Cancer, while progressing Anti-Virals and Neuro with the support of collaborators.  

Focusing on transforming cancer treatment for solid tumors

MicroQuin's orally available lead small molecule, SMQ-2174, exclusively induces rapid cancer death irrespective of the cancer type.

Cancer
bottom of page